Bone Therapeutics SA AI Price Prediction

The company is loss-making, as indicated by negative EPS and a PE ratio of 0.00, which typically reflects the market’s difficulty in valuing the equity on an earnings basis. With EPS at -0.77 and no sign of positive earnings, the underlying profitability profile appears weak and highly speculative. In the absence of revenue or margin details, the available metrics point to a structurally unprofitable situation with elevated risk.

• Negative EPS of -0.77 indicates ongoing losses and an absence of sustainable profitability.
• PE ratio of 0.00 suggests the stock is not being valued on an earnings basis, consistent with a loss-making or distressed company.
• Trading at €0.00 implies severe equity value erosion, often associated with restructuring, delisting risk, or near-insolvency conditions.

The stock is quoted at €0.00 and has shown 0.0% movement over the last month, which is more consistent with an illiquid or effectively non-trading security than with a healthy listed stock. The 200-day moving average at €0.06 versus a current price of €0.00 signals a substantial long-term downtrend and destruction of shareholder value. While the RSI of 54.84 appears neutral in isolation, it is largely irrelevant in the context of a stock that is effectively at zero.

• Current price of €0.00 with flat performance over the last month suggests extreme distress, potential suspension, or negligible trading activity.
• The 200-day moving average of €0.06 versus a current price of €0.00 indicates a pronounced long-term downtrend and loss of market confidence.
• RSI at 54.84 is nominally neutral, but technical oscillators lose interpretive power when the underlying price has effectively collapsed to zero.

Overall, the combination of a €0.00 share price, negative EPS, and the absence of positive earnings-based valuation metrics points to a highly distressed equity situation. Technical indicators confirm a long-term downtrend, and alternative data shows, at best, stable but unimpressive engagement with no clear growth momentum. Taken together, these factors support a bearish view on Bone Therapeutics SA’s stock from a risk–reward and sustainability perspective.

• The stock’s effective collapse to €0.00 and negative earnings profile dominate the investment case, signaling extreme risk and limited visible upside.
• Alternative data and engagement metrics are not strong or improving enough to offset the overwhelmingly negative financial and price signals.